Early Clinical PET Imaging Results with the Novel PHF-tau Radioligand [F-18]-T807

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2012 Dec 14

PMID 23234879

Citations 339

Authors

David T Chien

Shadfar Bahri

A Katrin Szardenings

Joseph C Walsh

Fanrong Mu

Min-Ying Su

William R Shankle

Arkadij Elizarov

Hartmuth C Kolb

Affiliations

Soon will be listed here.

Abstract

Aggregates of hyperphosphorylated tau (PHF-tau), such as neurofibrillary tangles, are linked to the degree of cognitive impairment in Alzheimer's disease. We have developed a novel PHF-tau targeting positron emission tomography imaging agent, [F-18]-T807, which may be useful for imaging Alzheimer's disease and other tauopathies. Here in, we describe the first human brain images with [F-18]-T807.

Citing Articles

Role of tau versus TDP-43 pathology on medial temporal lobe atrophy in aging and Alzheimer's disease.

Wisse L, Wuestefeld A, Murray M, Jagust W, La Joie R Alzheimers Dement. 2025; 21(2):e14582.

PMID: 39985478 PMC: 11846482. DOI: 10.1002/alz.14582.

A Cooperative Model for Symmetric Ligand Binding to Protein Fibrils.

Smith M, DeGrado W, Grabe M, Shoichet B bioRxiv. 2025; .

PMID: 39975185 PMC: 11838254. DOI: 10.1101/2025.01.29.635590.

Drug repurposing for Alzheimer's disease and other neurodegenerative disorders.

Cummings J, Zhou Y, Van Stone A, Cammann D, Tonegawa-Kuji R, Fonseca J Nat Commun. 2025; 16(1):1755.

PMID: 39971900 PMC: 11840136. DOI: 10.1038/s41467-025-56690-4.

PET, SPECT, and MRI imaging for evaluation of Parkinson's disease.

Gujral J, Gandhi O, Singh S, Ahmed M, Ayubcha C, Werner T Am J Nucl Med Mol Imaging. 2025; 14(6):371-390.

PMID: 39840378 PMC: 11744359. DOI: 10.62347/AICM8774.

Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders.

Mekala S, Wu Y, Li Y RSC Med Chem. 2024; .

PMID: 39678127 PMC: 11638850. DOI: 10.1039/d4md00576g.